Taysha Gene Therapies Prices $200M Public Offering at Discount, Funds Rett Syndrome Program
TSHA has more than doubled off its 52-week low of $2.25 on elevated volume (4.3× avg).
Summary
Taysha Gene Therapies priced a $200 million public offering of common stock and pre-funded warrants at a discount, aiming to fund the development and commercial launch of its lead Rett syndrome gene therapy, TSHA-102, and extend its cash runway.
Key Events · Financing and Capital Events · TSHA
-
Public Offering Priced
Taysha Gene Therapies finalized the pricing of its public offering, selling 32,500,001 shares of common stock at $6.00 per share and pre-funded warrants to purchase up to 833,333 shares at $5.999 per warrant.
-
Significant Dilution
The offering, including the underwriters' option, could result in the issuance of up to 38,333,334 new shares, representing approximately 13.3% dilution based on shares outstanding as of March 31, 2026.
-
Discounted Pricing
The offering price of $6.00 per share is at a discount to the last reported sale price of $6.94 on June 24, 2026, and today's price of $6.21.
-
Capital for TSHA-102 Development
The estimated net proceeds of $187.4 million (or up to $215.6 million if the underwriters' option is fully exercised) will fund regulatory, manufacturing, and anticipated commercial launch of TSHA-102 for Rett syndrome, extending the cash runway into the second half of 2028.
Analysis · TSHA · Life Sciences
Taysha Gene Therapies has finalized the pricing of its $200 million public offering, which is critical for funding the regulatory, manufacturing, and anticipated commercial launch of its lead gene therapy candidate, TSHA-102 for Rett syndrome. This capital raise extends the company's cash runway into the second half of 2028, providing essential resources following recent positive clinical trial news for TSHA-102. However, the offering involves significant dilution for existing shareholders, with up to 13.3% of new shares being issued, and is priced at a discount to the stock's recent trading levels, which may exert downward pressure on the share price in the short term.
At the time of this filing, TSHA was trading at $6.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $2.25 to $7.30. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.